002581 ST未名医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-3.628-6.879-14.929-0.61411.966
总资产报酬率 ROA (%)-3.120-6.058-12.770-0.52110.373
投入资产回报率 ROIC (%)-3.451-6.645-14.132-0.56611.071

边际利润分析
销售毛利率 (%)37.29479.78580.59678.65778.686
营业利润率 (%)-51.076-30.930-68.2559.43067.811
息税前利润/营业总收入 (%)-49.846-41.749-71.1785.60970.558
净利润/营业总收入 (%)-44.328-39.632-74.952-0.24069.203

收益指标分析
经营活动净收益/利润总额(%)123.62452.37557.758-1,464.805-75.986
价值变动净收益/利润总额(%)-14.432-42.915-55.1261,708.919169.396
营业外收支净额/利润总额(%)-5.56823.7416.352-164.6161.980

偿债能力分析
流动比率 (X)4.1989.0433.7181.4232.199
速动比率 (X)3.5178.0793.0791.2031.950
资产负债率 (%)10.0027.9066.99213.57110.359
带息债务/全部投入资本 (%)3.5570.3910.5667.0926.220
股东权益/带息债务 (%)2,674.19624,345.70017,332.7481,296.2691,490.292
股东权益/负债合计 (%)843.9121,108.0081,265.802612.512837.013
利息保障倍数 (X)34.04335.077-41.7192.74251.213

营运能力分析
应收账款周转天数 (天)164.921103.234125.947211.052255.369
存货周转天数 (天)210.117407.533356.911340.998283.525